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Objectives: To assess safety and outcomes of the novel 2-stage hepatectomy,
Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
(ALPPS), using an international registry.
Background: ALPPS induces accelerated growth of small future liver rem-
nants (FLR) to allow curative resection of liver tumors. There is concern about
safety based on reports of higher morbidity and mortality.
Methods: A Web-based data entry system was created with password
access and data pseudoencryption (NCT01924741). All patients with com-
plete 90-day data were included. Multivariate logistic regression analysis was
performed to identify independent risk factors for severe complications and
mortality and volume growth of the FLR.
Results: Complete data were available for 202 patients. A total of 141 (70%)
patients had colorectal liver metastases (CRLM). Median starting standard-
ized future liver remnants of 21% increased by 80% within a median of 7
days. Ninety-day mortality was 19/202 (9%). Severe complications including
mortalities (Clavien-Dindo ≥IIIb) occurred in 27% of patients. Independent
factors for severe complications were red blood cell transfusion [odds ratio
(OR), 5.2), ALPPS stage I operating time greater than 300 minutes (OR,
4.4), age more than 60 years (OR, 3.8), and non-CRLM (OR, 2.7). Age, use
of Pringle maneuver, and histologic changes led to less volume growth. In
patients younger than 60 years with CRLM, 90-day mortality was similar to
conventional 2-stage hepatectomies for CRLM.
Conclusions: This is the first analysis of the ALPPS registry showing
that ALPPS has increased perioperative morbidity and mortality in older
patients but better outcomes in patients with CRLM.
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D uring the last decade, 2-stage hepatectomy was established asa curative treatment strategy for patients with initially unre-
sectable bilobar liver tumors.1 An element of this strategy is portal
vein occlusion to induce hypertrophy of the future liver remnant
(FLR). Recently, a novel variant of 2-stage hepatectomy, termed “As-
sociating Liver Partition and Portal Vein Ligation for Staged Hep-
atectomy” (ALPPS), has been reported.2 ALPPS induces faster hy-
pertrophy of the FLR than the conventional 2-stage hepatectomy.3
In addition to occlusion of the right portal vein and cleaning of the
left liver from tumor, transection between the “deportalized” and the
normally vascularized (FLR) parts of the liver is performed at stage I.
Stage II follows with removal of the deportalized part of the liver
after rapid hypertrophy of the FLR, usually within 7 to 10 days after
stage I.4 Since its introduction, ALPPS has been adopted by many
surgeons worldwide.4–10
The initially reported mortality of 12%2 triggered an intense
debate about the safety of this procedure.3,10–12 The international
ALPPS registry was initiated in 2012 to systematically and uniformly
collect information from multiple centers worldwide. The registry
should enable surgeons to study a larger population to overcome
shortcomings inherent to small case series reports.13 Furthermore,
the registry may help refine patients’ selection for this complex pro-
cedure. The aim of this first analysis was to determine (1) perioper-
ative morbidity and mortality, (2) independent predictors for poorer
outcome, (3) overall survival and recurrence-free survival, and (4)
independent predictors for the rapid hypertrophy of the FLR.
MATERIALS AND METHODS
Study Design and Study Setting
Ethics approval was obtained for an online registry at the Ethics
Committee Kanton Zurich, Switzerland, and the study was registered
at Clinicaltrials.gov (NCT01924741). To establish the registry, an
electronic case report form using the clinical trials software SECU-
TRIAL (Interactive System, Berlin, Germany) was presented to se-
lected experts worldwide for approval (Scientific Committee of the
ALPPS Registry). Any center willing to report patients in the registry
was given access through the Web page www.alpps.net. Pseudoen-
cryption data for identification of patients are held by the centers. All
coinvestigators involved in data entry are listed in the ALPPS reg-
istry group author section later. Data were entered between October
2012 and December 2013. Completeness of data entry was monitored
through a query and answer system maintained by a dedicated study
nurse in Zurich. Data auditing was performed on a weekly basis by
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the registry administrators (E.S., V.A., D.R., and A.S.). Data export
and analysis were performed in January 2014.
Participants and Variables
All patients undergoing ALPPS were eligible. Centers per-
forming less than 8 ALPPS operations were considered low volume,
others high volume. This cutoff was based on the median number
of cases per center (n = 8). Data on patient demographics, tumor
type, comorbidities, volumetry, procedure details, pathology, com-
plications, survival, and recurrence were provided by participating
centers. Volumetric data were entered on the basis of imaging per-
formed in each center, and FLR volume is reported with tumors in the
FLR subtracted. To adapt liver volumes to metabolic demand, stan-
dardized total liver volume was calculated.14 To standardize kinetic
growth, a mean volume increase per day was calculated assuming a
linear growth model. Growth was expressed in cubic centimeter per
day and standardized future liver remnants (sFLR) increase per day
in percent.
Main outcome was 90-day mortality. Complications were
recorded using the Clavien-Dindo classification.15,16 We defined
severe complications as a complication grade of IIIb or greater as
in previous publications.15,17 Severe complications require general
anesthesia for intervention and also include mortality. To enable com-
parative analyses, we also analyzed complications of grade IIIa or
greater, because this was used in other studies also including inter-
ventions performed without general anesthesia.18 Further outcome
parameters included in-hospital mortality, 30-day mortality, overall
complications, postoperative liver and renal failure, and intensive
care unit and length of hospital stay. Postoperative liver failure was
defined according to the 50/50 criteria,19 renal failure as increase of
creatinine within 48 hours after surgery to more than 1.4 times of the
preoperative level.20
Bias and Study Size
All patients enrolled into the registry, except for those lack-
ing information about the procedure and 90-day survival status, were
included. Centers were encouraged to enter all cases of ALPPS per-
formed and not select patients on the basis of any criteria, specifically
outcome. Centers were contacted to confirm that they had entered all
ALPPS cases performed in their respective center and to complete
the 90-day survival status.
Quantitative Variables and Statistical Methods
The distribution of variables was analyzed using the
Kolmogorov-Smirnov test, and data are expressed using means and
standard deviation (SD) for normally distributed and median and in-
terquartile ranges for nonnormally distributed data. Uni- and mul-
tivariate linear and binary logistic regression analyses were per-
formed for severe complications including death during hospitaliza-
tion (≥grade IIIb). Data were reported as point estimates (odds ratios)
with 95% confidence intervals. P values less than 0.05 were consid-
ered as significant. Logistic regression analysis was performed for a
kinetic growth rate less than 0.02 per day. Kaplan-Meier method was
used for survival and recurrence-free survival. All statistical anal-
yses were performed using SPSS version 22 for Mac (IBM Corp.,
Armonk, NY).
RESULTS
Characteristics of Participants
Ninety-nine centers registered with the ALPPS registry, of
which 56 entered 255 patients undergoing ALPPS. Supplemental Dig-
ital Content Figure 1, available at http://links.lww.com/SLA/A620,
shows exclusion of patients due to incomplete data. A total of 202 pa-
tients from 41 centers provided complete data sets of procedures and
90-day survival status. Demographics are summarized in Table 1.
In 70% of patients, the indication for ALPPS was colorectal liver
metastases (CRLM). Ten centers (25%) performed more than 8 pro-
cedures. Details on patients with CRLM are given in Supplemental
Digital Content Table 1, available at http://links.lww.com/SLA/A619.
Operative Characteristics
As presented in Table 2, 4 cases in the registry were performed
laparoscopically and 1 with the assistance of a robot. None of these
5 cases had postoperative complications of IIIb or greater, and all
survived 90 days. One laparoscopically resected patient died after
181 days with complications from the resection of the primary colonic
tumor.
The different types of ALPPS performed are shown in Sup-
plemental Digital Content Figure 2, available at http://links.lww.com/
SLA/A620. The median sFLR size of the right hepatectomy ALPPS
(A), the right trisectionectomy ALPPS + segment 1 (B), and the
right trisectionectomy ALPPS − segment 1 (C) was 0.25, 0.20, and
TABLE 1. Main Characteristics of 202 Patients in the ALPPS
Registry
Variable of Interest All Patients (n = 202)
Age, median (IQR), yr 60 (53–68)
Sex, male/female, number (%) 121/81(60%/40%)
Ethnic origin
White, n (%) 188 (93)
Asian, n (%) 10 (5)
Other∗, n (%) 4 (2)
Tumor type
CRLM, n (%) 141 (70)
HCC, n (%) 17 (8)
PHCC, n (%) 11 (5)
IHCC, n (%) 8 (4)
NET, n (%) 8 (4)
Gallbladder cancer, n (%) 6 (3)
Others, n (%) 11 (5)
Charlson Index (1–14)†, median (IQR) 8 (6–9)
Histological abnormalities, data available
(100%)
n = 150 (100%)
Abnormal liver histology
(fibrosis/steatosis/chemotherapy-related
changes), n (%)
79 (52)
Location of ALPPS patients
Total centers (no. centers registered) 75
Total (no. patients/no. centers) 202/41
Europe (no. patients/no. centers) 136/27
South America (no. patients/no. centers) 43/4
North America (no. patients/no. centers) 13/4
Asia (no. patients/no. centers) 9/5
Middle East (no. patients/no. centers) 1/1
Year in which ALPPS was performed
2011, n (%) 28 (14)
2012, n (%) 112 (55)
2013, n (%) 62 (30)
Low- and high-volume centers
<8 procedures, no. patients/no. centers 75/31
≥8 procedures, no. patients/no. centers 127/10
“Data available” refers to the number of patients in the registry with complete
information about the respective variable.
∗Other include 3 African patients and 1 Indian patient.
†Charlson Index is a validated method to quantify comorbidities.
CRLM indicates colorectal liver metastasis; HCC, hepatocellular carcinoma;
IHCC, intrahepatic cholangiocarcinoma; IQR, interquartile range; NET, neuroen-
docrine tumor; PHCC, perihilar cholangiocarcinoma.
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TABLE 2. Main Operative Characteristics of 202 Patients in
the ALPPS Registry
Variable All Patients (n = 202)
Laparoscopic/robotic ALPPS, n (%) 5 (3)
Type of ALPPS∗
Right hepatectomy ALPPS, n (%) 106 (52)
Right trisectionectomy ALPPS + Sg 1,
n (%)
69 (34)
Right trisectionectomy ALPPS − Sg 1,
n (%)
17 (8)
Other types†, n (%) 10 (5)
Mean operative time ALPPS stage I,
minutes, mean (SD)
327 (±119)
Mean operative time ALPPS stage II,
minutes, mean (SD)
156 (±75)
Pringle maneuver, data available n = 134 (100%)
Performed in n (%) of cases 65 (49)
Cumulative time performed, minutes,
median (IQR)
30 (16–45)
CVP, data available n = 68 (100%)
mm Hg, median (IQR) 5 (3–6)
Blood loss ALPPS stage I, data available n = 159 (100%)
<100 mL, n (%) 23 (14)
101–600 mL, n (%) 77 (48)
601–1000 mL, n (%) 35 (22)
>1000 mL, n (%) 24 (15)
Blood loss ALPPS stage II, data available n = 145 (100%)
<100 mL, n (%) 60 (41)
101–600 mL, n (%) 67 (46)
601–1000 mL, n (%) 10 (7)
>1000 mL, n (%) 8 (6)
RBC transfusion ALPPS stage I n = 189 (100%)
Patients transfused, n (%) 53 (28)
Units of RBC, median (IQR) 3 (2–4)
RBC transfusion ALPPS Stage II, data
available
n = 184 (100%)
Patients transfused, n (%) 44 (24)
Units of RBC, median (IQR) 2 (2–3)
“Data available” refers to the number of patients in the registry with complete
information about the respective variable.
∗For type of ALPPS, see Supplemental Digital Content Figure S2, available at
http://links.lww.com/SLA/A620.
†Other types include single segment ALPPS and left ALPPS as shown in Supple-
mental Digital Content Figure S3, available at http://links.lww.com/SLA/A620.
ALPPS indicates Associating Liver Partition With Portal Vein Ligation for Staged
Hepatectomy; CVP, central venous pressure; IQR, interquartile range; RBC, red blood
cells; Sg, segment.
0.19, respectively. Five ALPPS procedures with single segment FLRs
and 1 left hepatectomy ALPPS were reported (Supplemental Digi-
tal Content Fig. 3, available at http://links.lww.com/SLA/A620). In
12% of patients, additional extrahepatic procedures were simulta-
neously performed, mainly resections of colorectal primaries dur-
ing stage I (Supplemental Digital Content Table 2, available at
http://links.lww.com/SLA/A619).
Biometric Changes of Liver Volumes
Mean weight, height, body surface area (Mosteller formula),
body mass index, and liver volumes are shown in Supplemental Dig-
ital Content Table 3, available at http://links.lww.com/SLA/A619.
Median starting FLR before stage I was 337 cm3 corresponding
to an sFLR of 0.21. Between stage I and II, the volume increased
by 80% (IQR 49%–116%) within a median time interval of 7 days
(interquartile range: 6–13 days) to a volume before stage II of
612 cm3 (468–720 cm3), corresponding to an sFLR of 0.40
(0.31–0.47).
Postoperative Outcomes
As shown in Table 3 both ALPPS stages were completed in
98% (197/202) of patients. Complications are shown in Table 3 and
details are listed in Supplemental Digital Content Table 4, available
at http://links.lww.com/SLA/A619. Considering both stages, 28% of
patients experienced severe complications including mortality (grade
≥IIIb). Perioperative 90-day mortality was 9%. Significant risk fac-
tors for severe complications were red blood cell transfusion [odds
ratio (OR), 5.26], duration of stage I surgery greater than 300 minutes
(OR, 4.42), age greater than 60 years (OR, 3.76), and non-CRLM
(OR, 2.73) (Fig. 1A). Severe complication rate was higher in pa-
tients with primary liver cancer than in those with CRLM (Fig. 1B).
Patients with CRLM aged 60 years and younger had a severe com-
plication rate of 16% and a 90-day mortality of 5.1%, both reflect-
ing significantly better results in comparison with others (Fig. 1C).
Length of intensive care unit and hospital stay after each stage
are given in Supplemental Digital Content Table S4, available at
http://links.lww.com/SLA/A619.
Survival
Overall survival of patients undergoing ALPPS at 1 and 2
years was 73% and 59%, respectively (Fig. 2A). Patients with CRLM
younger than 60 years had better survival than those with non-CRLM
or age more than 60 years (Figs. 2B, C). The combination of age
less than 60 years and CRLM showed better survival than all others
(Fig. 2D). An estimate of the proportion of patients surviving each
tumor type including numbers at risk is given at 1 and 2 years, if
available (Table 4).
Predictors of Hypertrophy
The results of the multivariate analysis for factors impacting on
kinetic growth are shown in Supplemental Digital Content Figure 4A,
TABLE 3. Main Postoperative Outcomes of 202 Patients in
the ALPPS Registry
Variable All Patients (n = 202)
Failure to reach stage II, n (%) 5 (2)
30-d mortality, n (%) 5 (2)
In-hospital mortality, n (%) 18 (9)
90-d mortality
In all patients n (%) 19 (9)
In CRLM, n (%) (no. total CRLM) 11 (8%) (n = 141)
In HCC, n (%) (no. total HCC) 2 (12%) (n = 17)
In PHCC, n (%) (no. total PHCC) 3 (27%) (n = 11)
In IHCC, n (%) (no. total IHCC) 1 (13%) (n = 8)
In NET, n (%) (no. total NET) 0 (0%) (n = 8)
In gallbladder cancer (%) (no. total
gallbladder cancer)
2 (33%) (n = 6)
In subgroup ≤60 yr + CRLM, n
(%), (no. total)
4 (5.1%) (n = 78)
Highest complication ≥grade IIIa in both stages
All patients, n (%) (no. total) 80 (40%) (n = 202)
In CRLM group, n (%) (no. total) 51 (36%) (n = 141)
In subgroup ≤60 yr + CRLM, n
(%) (no. total)
23 (29%) (n = 78)
Highest complication ≥grade IIIb in both stages
All tumor types, n (%) 56 (28%) (n = 202)
In CRLM group, n (%), (no. total) 30 (21%) (n = 141)
In subgroup ≤60 yr + CRLM, n
(%) (no. total)
12 (16%) (n = 78)
Grading of complications according to Clavien-Dindo classification.
CRLM indicates colorectal liver metastasis; HCC, hepatocellular carcinoma;
IHCC, intrahepatic cholangiocarcinoma; NET, neuroendocrine tumor; PHCC, peri-
hilar cholangiocarcinoma.
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FIGURE 1. A, Logistic regression analysis for severe complications and mortality (≥IIIb-V). “Operation duration” refers to ALPPS
stage I. B, Rate of severe complications and mortality for different tumor types. C, Rate of severe complications and mortality
for patients older than 60 years/60 years and younger, with the diagnosis of CRLM/non-CRLM. BMI indicates body mass index;
Ca, carcinoma; CI, confidence interval; CRLM, colorectal liver metastasis; HCC, hepatocellular carcinoma; IHCC, intrahepatic
cholangiocarcinoma; OR, odds ratio; PHCC, perihilar cholangiocarcinoma; Sg, segment.
available at http://links.lww.com/SLA/A620. Age greater than
60 years, use of the Pringle maneuver, and diseased liver parenchyma
(steatosis, fibrosis, chemotherapy-related changes) were significant
factors for reduced kinetic growth (<0.02 FLR per day). The as-
sociations of these factors and reduced kinetic growth are summa-
rized in Supplemental Digital Content Figures 4B–D, available at
http://links.lww.com/SLA/A620.
DISCUSSION
The first analysis of the International ALPPS registry presents
the currently largest studied population of ALPPS patients. The 90-
day mortality after ALPPS was 9%, and independent predictors for
severe complications during hospitalization were tumors other than
CRLM, age greater than 60 years, and 2 markers of complex liver
resections: need for intraoperative red blood cell transfusions and
stage I operations for more than 5 hours. Based on these findings,
we postulate that the observed elevated complication rate may be at-
tributable to both indications beyond CRLM and technical challenges
of ALPPS. The subgroup analysis revealed that patients with CRLM
younger than 60 years had significantly lower complication rates.
Although the large and multicenter study population of 202
patients represents the strength of this study, the shortcomings are
the inhomogeneity of the study population including patients with all
types of liver tumors and study centers with high and low volumes.
This is inherent in the study design due to the novelty of the procedure.
Another limitation is the incompleteness of data in some areas such
as laboratory values, which is likely related to the effort required for
the data entry. Also, data could not be verified by physical monitor
visits. Instead, weekly monitoring was performed through a query
and answer system, e-mails, and phone calls from the study center
in Zurich. Despite these limitations, this analysis currently represents
the best available data on ALPPS.
One central finding is the impressive hypertrophy of 80%
within a median of 7 days. This observation remains a robust phe-
nomenon across the experience with 178 patients with complete volu-
metric data sets. The median kinetic growth of 0.02 sFLR (interquar-
tile range: 0.01–0.03) provides the basis for the estimation of the
required time period for volume hypertrophy in ALPPS: for example,
a patient with a starting FLR of 15% has a 75% change to reach
the volume cutoff of 30% sFLR within 15 days after stage I. The
finding that Pringle maneuver and diseased liver are independently
associated with inferior FLR growth is consistent with experimental
studies showing that that warm ischemia and, for example, steatosis
reduce the regenerative capacity of rodent livers after resection.21,22
Although there is a consensus that standard liver resections
have a perioperative mortality of up to 3% in experienced centers,16,23
the mortality of complex liver resections is rarely reported and likely
to stand in the vicinity of 5% to 8%.1,18,24 However, reports on case
series of ALPPS have mentioned higher perioperative mortality rates
ranging between 12% and 28%.2,5,6,25
Kokudo and Shindoh13 recently made a call for a phase I pro-
cess before taking the next step to confirm the safety of the ALPPS by
providing an acceptable morbidity and mortality rate comparable with
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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FIGURE 2. Survival in ALPPS patients. A, Overall survival of ALPPS patients. B, Difference in survival for CRLM versus non-CRLM.
C, Difference in survival in patients with age greater than 60 years and 60 years and younger. D, Difference in survival in patients
with CRLM and age greater than 60 versus all others.
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TABLE 4. Survival and Disease-Free Survival in 202 Patients
in the ALPPS Registry
Patients According to Tumor Type All Patients (n = 202)
All patients 202
R-status available n = 185 (100%)
Incomplete resection (R1/R2), n (%) 16 (9)
Median follow-up, mo (IQR) 9 (6–13)
Median survival, mo 25
Survival at 1 yr (patients at risk) 73% (52)
Survival at 2 yr (patients at risk) 59% (5)
Median disease-free survival, mo 14
Disease-free survival at 1 yr (patients at
risk)
60% (27)
Disease-free survival at 2 yr (patients at
risk)
42% (1)
CRLM, no. patients 141
R-status available n = 130 (100%)
Incomplete resection (R1/R2), n (%) 12 (9)
Survival at 1 yr∗ (patients at risk) 76% (41)
Survival at 2 yr∗ (patients at risk) 62% (6)
Disease-free survival at 1 yr∗ (patients at
risk)
59% (28)
Disease-free survival at 2 yr∗ (patients at
risk)
41% (9)
Subgroup <60 yr + CRLM only, number of
patients
78
R-status available n = 73 (100%)
Incomplete resection (R1/R2), n (%) 6 (8)
Disease-free survival at 1 yr∗ (patients at
risk)
55% (17)
Disease-free survival at 2 yr∗ (patients at
risk)
36% (7)
Survival at 1 yr∗ (patients at risk) 88% (33)
Survival at 2 yr∗ (patients at risk) 74% (10)
HCC, no. patients 17
R-status available n = 15 (100%)
Incomplete resection (R1/R2), n (%) 0
Disease-free survival at 1 yr∗ (patients at
risk)
87% (1)
Survival at 1 yr∗ (patients at risk) 61% (1)
PHCC, no. patients 11
R-status available n = 9 (100%)
Incomplete resection (R1/R2), n (%) 2 (22)
Disease-free survival at 1 yr∗ NA†
Survival at 1 yr∗ NA†
IHCC, no. patients 8
R-status available n = 7 (100%)
Incomplete resection (R1/R2) in % 1 (14%)
Disease-free survival at 1 yr∗ (patients at
risk)
31% (1)
Survival at 1 yr∗ (patients at risk) 73% (1)
NET, no. patients 8
R-status available n = 8 (100%)
Incomplete resection (R1/R2), n (%) 1 (13)
Disease-free survival at 1 yr∗ (patients
at risk)
83% (5)
Survival at 1 yr∗ (patients at risk) 73% (1)
Gallbladder cancer, no. patients 6
R-status available n = 6 (100%)
Incomplete resection (R1/R2), n (%) 0
Disease-free survival at 1 yr∗ NA†
Survival at 1 yr∗ NA†
∗Cumulative proportion surviving at the time according to Kaplan-Meier estimates.
†Not available: follow-up not long enough to assess.
CRLM indicates colorectal liver metastases; HCC, hepatocellular carcinoma;
IHCC, intrahepatic cholangiocarcinoma; IQR, interquartile range; NET, neuroen-
docrine tumor; PHCC, perihilar cholangiocarcinoma.
current clinical practice. What constitutes an “acceptable” periopera-
tive morbidity/mortality rate remains arguable, because it is difficult
to identify a population that matches ALPPS patients.25 Parameters
such as tumor load and type and FLR size should be similar when
patients with ALPPS are compared with patients with conventional 2-
stage procedures. A recently published study from the MD Anderson
group comparing portal vein embolization (PVE) and staged hepate-
ctomy from their own institution (n = 141) with the inaugural ALPPS
series from Germany (n = 25) demonstrated a lower rate of complica-
tions of grade III or greater (33% vs 40%) and 90-day mortality (6%
vs12% for the PVE cohort, although the difference did not reach sta-
tistical significance).26 The figure of grade IIIa of 40% or greater from
the inaugural ALPPS series is consistent with this registry analysis, in
which 42% of the patients developed a grade IIIa or higher complica-
tion. The main issue with the MD Anderson study is the lack of com-
parability of groups. For example, 78% (n = 112) of the 144 patients
in the PVE cohort underwent only an interventional embolization, fol-
lowed by a curative resection without the need for two hepatectomies.
This was possible only because those patients did not require a “clean-
ing” of the FLR, which is a common feature of most ALPPS patients.
ALPPS patients receiving 2 operations have obviously a higher risk
for more complications. On the contrary, as we have shown recently,
patients undergoing ALPPS have a higher chance to achieve complete
tumor resection despite having more complications.25 The benefit of
achieving complete resection has to be weighed against the risk of
complications of more extensive procedures. A conclusive compar-
ison of the PVE cohorts with ALPPS cohorts with mixed tumors is
difficult.
The next step forward is to explore efficacy of ALPPS in an
randomized controlled trial (RCT).27 To be on the safer side, a def-
inition of inclusion criteria is key to establish a definitive role for
ALPPS. ALPPS should be randomly compared with other types of 2-
stage approaches including PVE and PVL with cleaning of the FLR.
Such a study ought to be limited to patients, who have shown simi-
lar outcome in the registry when compared with historical series of
conventional 2-stage hepatectomy. The subgroup of patients younger
than 60 years with CRLM in the registry not only has similar tumor
characteristics of CRLM but also perioperative outcome comparable
with the largest reported series of 2-stage hepatectomies for CRLM
(n = 65),18 including a 90-day mortality rate of 5.1 versus 6.4%,
respectively. An important drawback of the conventional approach,
as also documented in our previous comparative analysis,25 is that
only about two-thirds of patients reached stage II,18 whereas 98% of
the patients were offered stage II in the ALPPS registry. This find-
ing is likely to have a major impact an intent-to-cure analysis in an
RCT. Only a prospective randomized controlled trial would make a
conclusive risk benefit analysis for ALPPS possible.
Another important finding of the registry is that patients with
cholangiocarcinoma and gallbladder cancer had an inferior outcome,
which is similar to previously reported case series.4,5,9,28 It is a weak-
ness of this study that this group comprises only 25 of 202 patients
(12%). It is, however, fair to conclude that ALPPS should be per-
formed with great caution in this population. It seems that ALPPS
might have been overused in elderly patients with extensive disease
burden of liver tumors, specifically primary hepatic tumors, as a
“magic bullet” by clinicians during the early phase of enthusiasm
about rapid hypertrophy. It was tempting to speculate that the “aux-
iliary liver” in place after stage I would allow any extent of liver
resection in elderly patients with comorbidities otherwise prohibitive.
Information on long-term survival after ALPPS is sparse due
to low numbers of patients in single center series, the heterogenous
population regarding the type of tumors, and its recent introduction.2
ALPPS patients with CRLM have a 1- and 2-year survival of 88%
and 74%, respectively, and a median survival of 24 months. These
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figures compare favorably with the MD Anderson CRLM 2-stage
cohort with a 3-year survival of 67%.18 The survival of patients with
CRLM younger than 60 years was significantly better than that of
other subgroups. ALPPS is a physiologically challenging operation,
and elderly patients seem to be doing worse both perioperatively and
as far as medium-term survival are concerned. Survival data on other
indications than CRLM are inconclusive at this point due to the low
number of patients.
Beside patient survival, disease-free survival (DFS) is another
key parameter in assessing the oncological value of ALPPS. To our
knowledge, this is the first report on DFS after ALPPS. There is
still a paucity of data on DFS in patients with CRLM, who undergo
conventional 2-stage hepatectomy. In a 2-center study including 35
patients, DFS after 2-stage hepatectomy for CRLM was 85% and 68%
at 1 and 2 years, respectively.24 In a larger cohort,18 the rate of DFS of
those patients, who completed the second stage (n = 47), reached 39%
at 1 year and 20% at 3 years.18 Again, these studies do not report DFS
in an intent-to-cure analysis but only in patients, who underwent both
stages. In comparison, the 1- and 2-year DFS in the ALPPS registry
for patients with CRLM of 59% and 41%, respectively, with a median
DFS of 14 months, seems acceptable, particularly considering that
almost all patients could eventually benefit from a curative resection.
The concern raised on the basis of small data sets about high tumor
recurrence after ALPPS seems currently unwarranted.11,29
Another interesting finding of the registry analysis was that
intraoperative red blood cell transfusion requirements and long op-
erative time during stage I were independent factors for more com-
plications. These findings may point to the technical complexity of
ALPPS. Improvements of outcomes with ALPPS should, therefore,
be expected not only from more restrictive indications but also from
technical refinements. There are too few laparoscopic cases reported
in the registry to draw any firm conclusions.
CONCLUSIONS
The analysis of the first 202 patients of the international ALPPS
registry shows feasibility of ALPPS with a progression of the stage
II of 98% and an overall mortality of 9%. In patients with CRLM
younger than 60 years, however, an outcome comparable with con-
ventional 2-stage hepatectomies may be expected. To move forward,
a randomized trial using strict inclusion criteria should be performed.
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DISCUSSANTS
F. R. Pruvot (Lille, France):
Congratulations to Dr. Schadde and Pierre Alain Clavien, and
thank you to the ESA committee for giving me the privilege to discuss
this very relevant article.
Briefly, ALPPS has emerged as a new procedure to, first, bypass
insufficient remnant volume and, second, to shorten the time interval
within a two-stage resection. Immediately, the question has been
raised, pertaining to its efficacy on remnant hypertrophy, mortality,
morbidity, and, of course, impact on survival. Although some data
are missing, the article provides answers to most questions and is
an essential step before ALPPS becomes a standard procedure, with
rates of 9% of mortality, 27% of severe morbidity, and a focus on
CRLM.
I would like to make two preliminary comments:
First, the choice of the methodology used, rendering it a
prospective ongoing study rather than a randomized trial compar-
ing ALPPS to a classical resection, is correct. I think that it will be
difficult to set up a randomized trial and choose which classical re-
section arm is the best—portal embolization with a 1-stage curative
resection or a 2-stage with portal embolization during interval; uni or
bilateral lesions? Second, which is more efficient, choosing ALPPS
by principle, or rescue-ALPPS, after a lack of postembolization
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hypertrophy, or finally an intraoperative decision for ALPPS? For
example, what would you do, if a patient would clearly benefit from
ALPPS hypertrophy after embolization as he has been included within
classical arm? In an intention to treat, randomization could give some
ethical trouble.
Second, only 3 French centers have contributed to the registry.
For, in February 2013, as the actual president of the French HPB
association, I proposed analyzing them in a multicentric survey of
ALPPS. Sixty two French patients were analyzed, who now make up
more than 75 to be later added to the international registry.
I have 1 question concerning the methodology:
Do you favor the “classical” standardized volumetry calcula-
tion, instead of the “remnant to body weight ratio”? As you know, the
ratio of body weight was the methodology used by Schnitzbauer in
the initial ALPPS report. This ratio to body weight is more accurate,
especially in very low volumes. In your series, in which the range
of the baseline remnant volume in the standardized calculation was
between 17% and 27%, which is on both side of the classical cutoff
20% to 25%; remnant volume of the body weight ratio was calcu-
lated as below 0.5% for all. Furthermore, in your series, I could notice
a high proportion (44%) of simple right-hepatectomies, a resection
that usually gives a sufficient remnant volume. Could you comment
on this?
I have 3 questions concerning the results:
Apparently no postoperative factor was significant for mor-
bimortality. In our French multicentric series, infected and/or bilious
peritoneal fluid at stage 2 was the only predictor of Clavien type 3 or
more, by multivariate analysis. Did you also analyze these data?
You did not find that the future liver remnant at baseline was
a significant parameter for morbidity, but, how about kinetic growth?
In other words, independently from baseline value, is a slow kinetic
growth needed to postpone stage 2, or should we use liver scintigraphy
to estimate liver function?
The decision to use ALPPS, instead of performing a classical
portal embolization and a 1- or 2-stage resection, is mainly preopera-
tive. However, 2 of the 3 significant multivariate factors for predicting
ALPPS morbidity are intraoperative ones, that is, the transfusion and
operating time. This is comparable with 2 of the 3 significant factors
for a lack of hypertrophy, namely, the use of the Pringle maneuver,
the quality of the liver parenchyma (usually difficult to assess pre-
operatively). So, in these conditions, how would you preoperatively
estimate the risks of ALPPS, in comparison with a classical strategy?
Finally, I have 2 questions concerning the indications and
strategy:
Taking into account the oncological principle of dissection for
hilar cholangiocarcinoma may be conflicting with the transection of
ALPPS; do you think ALPPS is contraindicated in the resection of
bile duct tumors?
Finally, ALPPS had a 3.76 odd ratio for more severe morbidity
in patients older than 60 years. Is an age of more than 60 years a
contraindication for ALPPS?
Once again, thank you for your essential work. It is a major
contribution in the field of HPB surgery.
Response From E. Schadde (Zurich, Switzerland):
Thank you for these questions, Professor Pruvot. First, with
regard to the volumetry question, we gave the data on the liver-
remnant-to-body weight ratio as well in the article. We did use the
sFLR, as it is done by the MD Anderson group, but we provided all
the parameters that we could. Your question about the simple right
hepatectomy is important because the majority of ALPPS cases in the
study turned out to be “ALPPS” right hepatectomies. However, when
you look at the low FLR volumes, you will see that these were not
normal right hepatectomies; the low volumes were due to large tumor
resections within the future liver remnant, which led to really exten-
sive removals of liver parenchyma but were formally classified by the
surgeons entering them, correctly, as right hepatectomies, because the
transection went along Cantlie line.
With regard to your second question about the infected fluid,
we did not collect data on the infected fluid. When we initiated the
registry, which we actually did simultaneously with the preparation of
the randomized trial, we did not think of this. So, we have no entries
about culture results. I do have results from Zurich, but they are just
a small subgroup of the analysis, and there are not enough events to
use them as an endpoint in a multivariate analysis.
Your third question regards kinetic growth and, more specifi-
cally, whether it is a risk factor. Using complications greater than 3B
as an endpoint, we could not identify kinetic growth as a risk factor.
But, what was interesting was the low baseline FLR before stage II,
which you addressed in the next question. This is a risk factor for liver
failure, which does not appear in the article, because we are currently
analyzing the entire series with different endpoints. We do find that
low baseline FLR before a stage II resection is a risk factor for liver
failure. So, we could advise surgeons to be generous with the volume
before stage II, when performing ALPPS.
In terms of what to do with the fact that Pringle and the quality
of the liver parenchyma are risk factors for kinetic growth still needs
to be found. Does Pringle really reduce the speed of kinetic growth
between the 2 stages? This is, indeed, questionable, but this is what
the multivariate analysis suggested. The role of the quality of the liver
parenchyma, on the contrary, did not surprise us, and this can be well
assessed preoperatively.
Your next question is an important one: Is ALPSS contraindi-
cated in Klatskin tumors? It is difficult for a surgeon to tell other
surgeons that a type of tumor is a contraindication for ALPPS; there
have been successful cases performed. However, as you know from
the literature, the German group in Tu¨bingen has also published a
series on patients, operated with Klatskin tumors, with high mor-
bidity and mortality rates; they were extremely concerned about the
patients with transhepatic drains due to cholestasis before ALPPS.
We should be very cautious with these patients because many, who
have explored ALPPS in this area, have either had mortalities or
severe morbidities in this patient population. The Tu¨bingen group
concluded that it is best to avoid ALPPS in patients with cholestasis
and biliary drains, but we cannot support this with data, because we
have not specifically analyzed how many patients had drains or how
many had contaminated bile systems.
With regard to your final question about age, we are currently
having this exact discussion about whether we should limit this pro-
cedure to patient younger than 60 years of age. About half of the
patients in our series are older than 60 years, as generally are our pa-
tients with colorectal liver metastases. We should probably be aware
that patients older than 60 years do not have much reserve for this
operation, as ALPPS is physiologically a very challenging operation.
DISCUSSANTS
A. Pinna (Bologna, Italy):
Thank you for this very nice presentation. I just have 2 quick
questions. First, should patients with jaundice be drained before an
ALPPS procedure? Second, when you considered patients older than
60 years, do you think that they failed because of hemodynamical
instability after the resection, or was the remnant liver unable to
increase its functional volume? In other words, is it the age of the
cells or the state of the heart that really matters?
Response From E. Schadde (Zurich, Switzerland):
Thank you, Professor Pinna, for these 2 questions. As far as
patients with jaundice are concerned, I have previously addressed
this question. We should be careful with patients with external biliary
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drains, when performing ALPPS. Second, with regard to age, I would
answer this question in a very general way. ALPPS is a physiologically
challenging operation, which is more difficult to tolerate for someone,
who is aged 70 years rather than 40 years. If things go wrong and
you have an infection with ALPPS, when you’re older than 70 years,
your risk of developing a severe complication is very high. Thus, the
general capability of a patient to tolerate a septic complication is what
matters, whether it is due to the liver cells or the heart.
DISCUSSANTS
E. Barroso (Lisbon, Portugal):
Let me say something strong—ALPPS is the last option, or
the ultimate possibility to cure some patients; it’s not a new operation
that you can utilize before you try to do a portal vein embolization. I
think that it’s not ethical to propose this kind of operation to a patient,
without first proposing a portal vein embolization. Why not try per-
forming a hepatic vein embolization, before ALPPS? Our results were
presented in IHPBA, in Korea, stating that before we can consider
ALPPS, after portal vein embolization, we need to try hepatic vein
embolization to improve the functional liver reserve. Frequently, we
avoid operating patients with the ALPPS technique. Finally, from this
report, do you think that the quality of the response to portal vein em-
bolization is also a predictor of what is going to happen with ALPPS?
If the liver volume is not sufficient, after portal vein embolization,
what is the criterion to propose as a last option?
Response From E. Schadde (Zurich, Switzerland):
Thank you. I will respond to your last question first. Several
groups have published reports on salvage ALPPS, or when portal
vein embolization does not work and ALPPS is attempted as a rescue
approach. There are very few reports in total, but they show that if
portal vein embolization has not worked, then ALPPS does work.
The successful cases we have performed in Zurich and elsewhere
support this. In your first question, you proposed to limit ALPPS
to a salvage approach, because everything else should be used be-
fore it. There are certain technical situations, where you would prefer
ALPPS, especially when you discuss this topic with those, who have
much experience with this operation. We should consider portal vein
embolization and portal vein ligation the standards, against which
ALPPS needs to be tested. This is exactly why we propose a random-
ized trial.
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